Abbot moved from 24th to 20th in 2016, and there’s every indication that by 2018 it will have risen higher in the ranks, thanks to its $25 billion acquisition of St. Jude Medical in January 2016.
In August, the FDA approved HeartMate 3, a bridge-to-transplant cardiac assist device that pumps blood for heart-failure patients using a fully magnetically levitated impeller that simulates the beating of a heart. The HeartMate 3 device is among key products in the St. Jude Medical portfolio, along with the other major launch this year, Tacticath, a contact force enabled catheter.
And Abbott is also making moves in the diabetes space, inking a deal with Bigfoot Biomedical, integrating its FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions.
* Revenues from Abbott’s medical device segment.
|Key Personnel: Miles White, chairman & CEO; Hubert Allen, EVP, general counsel & secretary; Brian Blaser, EVP, diagnostics; John Capek, EVP, ventures; Robert Ford, EVP, medical devices; Stephen Fussell, EVP, HR; Andrew Lane, EVP, established pharmaceuticals; Heather Mason, EVP, nutritional; Brian Yoor, EVP, finance & CFO; Roger Bird, SVP, U.S. nutrition; Jaime Contreras, SVP, core laboratory diagnostics, commercial operations; Denis Gestin, SVP, global commercial integration; Elaine Leavenworth, SVP, chief marketing & external affairs officer; Joseph Manning, SVP, international nutrition; Corlis Murray, SVP, quality assurance, regulatory & engineering services; Daniel Salvadori, SVP, established pharmaceuticals, Latin America; Jared Watkin, SVP, diabetes;|
100 ABBOTT PARK ROAD
North Chicago, Illinois